Morphic Holding, Inc. (MORF): Price and Financial Metrics
MORF Price/Volume Stats
| Current price | $29.51 | 52-week high | $63.08 |
| Prev. close | $28.66 | 52-week low | $19.34 |
| Day low | $28.26 | Volume | 641,800 |
| Day high | $29.55 | Avg. volume | 511,121 |
| 50-day MA | $34.95 | Dividend yield | N/A |
| 200-day MA | $36.50 | Market Cap | 1.48B |
MORF Stock Price Chart Interactive Chart >
Morphic Holding, Inc. (MORF) Company Bio
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Latest MORF News From Around the Web
Below are the latest news stories about MORPHIC HOLDING INC that investors may wish to consider to help them evaluate MORF as an investment opportunity.
Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 92.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
We're Not Very Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 160.84%: Read This Before Placing a BetThe consensus price target hints at a 160.8% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Morphic to Present at November Investor ConferencesWALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Jefferies London Healthcare Conference Fireside Chat Date: Tuesday, November 14, 2023Time: 5:00 PM GMT/12:00 PM ETA live webcast of |
MORF Price Returns
| 1-mo | -14.59% |
| 3-mo | 8.65% |
| 6-mo | 43.74% |
| 1-year | -30.45% |
| 3-year | -46.42% |
| 5-year | N/A |
| YTD | 2.18% |
| 2023 | 7.96% |
| 2022 | -43.54% |
| 2021 | 41.22% |
| 2020 | 95.51% |
| 2019 | N/A |
Loading social stream, please wait...